Dutch court halts Merck’s Keytruda SC in multiple EU markets
A Dutch court ruled Merck infringed Halozyme's patent and issued an injunction against Keytruda SC in eight EU markets. Merck must stop manufacturing and selling the subcutaneous version. The IV version remains available. Halozyme also sued Merck in the U.S. for patent infringement.
How this was made
The 30-second read
Why it matters
The injunction blocks Merck's SC launch, preserving Halozyme's patent rights and opening possible licensing opportunities.
Market read
The ruling creates immediate downside risk for Merck's oncology pipeline in Europe while boosting Halozyme's strategic position.
What to watch
Potential settlement negotiations could generate cash for Merck and licensing income for Halozyme.
Background
Merck's subcutaneous formulation of Keytruda was slated for launch across Europe. Halozyme holds patents on the MDASE technology used in the formulation.
Ticker impact
Dutch court injunction halts Merck's launch of Keytruda subcutaneous in eight EU markets.
likely pressure as the market prices in the loss of SC launch revenue.
The injunction stops Merck from selling a new formulation in major markets, reducing near‑term revenue potential.
Halozyme wins Dutch court injunction against Merck's Keytruda SC in Europe.
likely upside as the market values the strengthened patent position.
The court ruling validates Halozyme's patent and may lead to licensing fees or settlements.
Market effects
Biotech and oncology sectors may see heightened focus on patent risk.
European markets for oncology drugs could see short‑term volatility.
Keytruda is a global oncology product; the injunction may affect Merck's worldwide pipeline expectations.
Counterpoint
Merck may accelerate IV Keytruda sales or shift focus to other indications, mitigating impact.
Key entities
- CompanyMerck & Co.
Pharmaceutical giant facing injunction on Keytruda SC.
- CompanyHalozyme Therapeutics
Biotech firm enforcing its MDASE patent.
